As with this too... Amarantus continues the dev
Post# of 30066
Posted On: 10/05/2014 5:24:25 PM
As with this too...
Amarantus continues the development of LymPro, we will need to confirm the diagnoses of LymPro-positive subjects in biomarker-identified cohorts in order to initially demonstrate concordance with current FDA-approved gold-standard in-life diagnosis paradigm for Alzheimer’s disease. To that end, we achieved our objective, as the KOL community was extremely impressed that with a single marker we were able to show a highly statistically significant differentiation between Alzheimer’s and a healthy control, and believe that collaborators in the fall will be available for the CLIA-enabling study we will be running at our prospective partner’s laboratory.
While we continue to believe that there are other stimulation conditions of the assay under which we may see improved performance of LymPro (and we have already filed IP to cover these concepts), we could not reference anything other than the published literature when convincing the KOL community that LymPro is worthy of inclusion in leading edge diagnostic trials. Our strategy was successful and we expect significant collaborations to emerge as a result.
In summary, we are extremely pleased with the data we presented to the KOL community last week at #C4CT, and we achieved our strategic objective of convincing those KOLs that LymPro is worthy of being included in already-enrolling PET Alzheimer’s clinical studies.
See more at: http://www.thechairmansblog.com/amarantus-bio...JV3wy.dpuf
Amarantus continues the development of LymPro, we will need to confirm the diagnoses of LymPro-positive subjects in biomarker-identified cohorts in order to initially demonstrate concordance with current FDA-approved gold-standard in-life diagnosis paradigm for Alzheimer’s disease. To that end, we achieved our objective, as the KOL community was extremely impressed that with a single marker we were able to show a highly statistically significant differentiation between Alzheimer’s and a healthy control, and believe that collaborators in the fall will be available for the CLIA-enabling study we will be running at our prospective partner’s laboratory.
While we continue to believe that there are other stimulation conditions of the assay under which we may see improved performance of LymPro (and we have already filed IP to cover these concepts), we could not reference anything other than the published literature when convincing the KOL community that LymPro is worthy of inclusion in leading edge diagnostic trials. Our strategy was successful and we expect significant collaborations to emerge as a result.
In summary, we are extremely pleased with the data we presented to the KOL community last week at #C4CT, and we achieved our strategic objective of convincing those KOLs that LymPro is worthy of being included in already-enrolling PET Alzheimer’s clinical studies.
See more at: http://www.thechairmansblog.com/amarantus-bio...JV3wy.dpuf
(0)
(0)